Your browser doesn't support javascript.
loading
Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Li, Guilian; Xu, Zhengquan; Jiang, Yi; Liu, Haican; Zhao, Li-Li; Li, Machao; Xu, Donglei; Zhao, Xiuqin; Liu, Zhiguang; Wang, Ruibai; Wan, Kanglin.
Afiliación
  • Li G; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Xu Z; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Jiang Y; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Liu H; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Zhao LL; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Li M; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Xu D; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Zhao X; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Liu Z; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Wang R; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
  • Wan K; Tuberculosis branch, State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing
Int J Antimicrob Agents ; 54(5): 642-646, 2019 Nov.
Article en En | MEDLINE | ID: mdl-31200023
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Capreomicina / Clofazimina / Tuberculosis Resistente a Múltiples Medicamentos / Moxifloxacino / Mycobacterium tuberculosis / Antituberculosos Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Int J Antimicrob Agents Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Capreomicina / Clofazimina / Tuberculosis Resistente a Múltiples Medicamentos / Moxifloxacino / Mycobacterium tuberculosis / Antituberculosos Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Int J Antimicrob Agents Año: 2019 Tipo del documento: Article